Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 heart disease and stroke statistics: a report of us and global data from the american heart association. Circulation. 2024;149(8):e347–913.

Article  PubMed  Google Scholar 

Ajala ON, Everett BM. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep. 2020;22(11):66.

Article  CAS  PubMed  Google Scholar 

Virchow R, Cellular pathology [Christmas Summary Classics]: CreateSpace Independent Publishing Platform; 2013.

Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–26.

Article  CAS  PubMed  Google Scholar 

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

Article  CAS  PubMed  Google Scholar 

Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004–13.

Article  CAS  PubMed  Google Scholar 

Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578–89.

Article  CAS  PubMed  Google Scholar 

Khan MS, Talha KM, Maqsood MH, Rymer JA, Borlaug BA, Docherty KF, et al. Interleukin-6 and cardiovascular events in healthy adults: MESA. JACC Adv. 2024;3(8):101063.

Article  PubMed  PubMed Central  Google Scholar 

Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24.

Article  PubMed  Google Scholar 

Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728–46.

Article  CAS  PubMed  Google Scholar 

Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020;72(4):561–76.

Article  CAS  PubMed  Google Scholar 

Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–9.

Article  CAS  PubMed  Google Scholar 

Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82(4):279–85.

Article  PubMed  Google Scholar 

Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117(11):e138–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Del Giudice E, Sota J, Orlando F, Picciano L, Cimaz R, Cantarini L, et al. Off-label use of canakinumab in pediatric rheumatology and rare diseases. Front Med (Lausanne). 2022;9:998281.

Article  PubMed  Google Scholar 

Ridker PM. Canakinumab for residual inflammatory risk. Eur Heart J. 2017;38(48):3545–8.

Article  CAS  PubMed  Google Scholar 

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.

Article  CAS  PubMed  Google Scholar 

Sehested TSG, Bjerre J, Ku S, Chang A, Jahansouz A, Owens DK, et al. Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events. JAMA Cardiol. 2019;4(2):128–35.

Article  PubMed  PubMed Central  Google Scholar 

Zomer E, Liew D, Tonkin A, Trauer JM, Ademi Z. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. Int J Cardiol. 2019;285:1–5.

Article  PubMed  Google Scholar 

Moroni F, Corna G, Del Buono MG, Golino M, Talasaz AH, Decotto S, et al. Impact of C-reactive protein levels and role of anakinra in patients with ST-elevation myocardial infarction. Int J Cardiol. 2024;398:131610.

Article  PubMed  Google Scholar 

Zubirán R, Neufeld EB, Dasseux A, Remaley AT, Sorokin AV. Recent advances in targeted management of inflammation in atherosclerosis: A narrative review. Cardiol Ther. 2024;13(3):465–91.

Article  PubMed  PubMed Central  Google Scholar 

McKie EA, Reid JL, Mistry PC, DeWall SL, Abberley L, Ambery PD, et al. A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS ONE. 2016;11(3):e0150018.

Article  PubMed  PubMed Central  Google Scholar 

Wlodek E, Kirkpatrick RB, Andrews S, Noble R, Schroyer R, Scott J, et al. A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function. PLoS ONE. 2021;16(3):e0247972.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Zoete MR, Palm NW, Zhu S, Flavell RA, Inflammasomes. Cold Spring Harb Perspect Biol. 2014;6(12):a016287.

Article  PubMed  PubMed Central  Google Scholar 

Chen P, Li X. NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies. Front Pharmacol. 2024;15:1430236.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine Cardiovasc Disease: In-Depth Rev Circulation. 2022;145(1):61–78.

CAS  Google Scholar 

Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10.

Article  CAS  PubMed  Google Scholar 

Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.

Article  CAS  PubMed  Google Scholar 

Opstal TSJ, van Broekhoven A, Fiolet ATL, Mosterd A, Eikelboom JW, Nidorf SM, et al. Long-term efficacy of colchicine in patients with chronic coronary disease: insights from lodoco2. Circulation. 2022;145(8):626–8.

Article  PubMed  Google Scholar 

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.

Article  CAS  PubMed  Google Scholar 

Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the colchicine cardiovascular outcomes trial (COLC